Fig. 6From: Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacologyKEGG enrichment of core genes. a KEGG pathway enrichment of core genes. b. EGFR tyrosine kinase inhibitor resistance pathway. c Non-small cell lung cancer pathwayBack to article page